SHADE UVAGUARD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SHADE UVAGUARD (SHADE UVAGUARD).
SHADE UVAGUARD is a sunscreen product containing chemical UV filters such as avobenzone, octinoxate, and oxybenzone. These organic compounds absorb UV radiation and convert it into heat, preventing DNA damage. Avobenzone absorbs UVA rays, while octinoxate and oxybenzone absorb UVB rays. The combination provides broad-spectrum protection.
| Metabolism | Topical UV filters are minimally absorbed; if absorbed, they are metabolized in the liver via cytochrome P450 enzymes (e.g., CYP3A4). Excretion is primarily renal. |
| Excretion | Renal: <1% unchanged; Biliary/fecal: negligible; Primarily remains on skin surface and is removed via washing or sloughing. |
| Half-life | Not applicable (topical, non-systemic); if absorbed, estimated <1 hour. |
| Protein binding | Not applicable (negligible systemic absorption). |
| Volume of Distribution | Not applicable (topical). |
| Bioavailability | Not applicable; negligible systemic absorption (<0.1%). |
| Onset of Action | Immediate upon application (physical sunscreen). |
| Duration of Action | Up to 2 hours; less if swimming or sweating. |
Topical application of 2 mg/cm² to all sun-exposed areas 15 minutes before sun exposure; reapply every 2 hours and after swimming or sweating.
| Dosage form | LOTION |
| Renal impairment | No dose adjustment required for renal impairment as systemic absorption is negligible. |
| Liver impairment | No dose adjustment required for hepatic impairment as systemic absorption is negligible. |
| Pediatric use | Same as adult dosing for children aged 6 months and older; apply 2 mg/cm² to exposed skin. For infants under 6 months, use minimal application and avoid direct sun exposure. |
| Geriatric use | No specific dose adjustment; standard topical application recommended. Ensure adequate coverage due to age-related skin thinning and reduced melanin. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SHADE UVAGUARD (SHADE UVAGUARD).
| Breastfeeding | Excretion into breast milk is unknown. M/P ratio not determined. Use caution in nursing mothers due to potential for skin irritation and systemic absorption. |
| Teratogenic Risk | No known human teratogenic effects; insufficient data for first trimester. Second and third trimesters: no fetal abnormalities reported. However, fetal exposure via transdermal absorption is minimal. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to any ingredient. Avoid use in infants under 6 months of age per FDA guidelines.
| Precautions | Avoid contact with eyes. Discontinue use if rash or irritation occurs. Do not use on damaged or broken skin. Reapply every 2 hours and after swimming or sweating. Keep out of reach of children. Avoid prolonged sun exposure. Not intended for ingestion. |
Loading safety data…
| No specific monitoring required beyond standard prenatal care. Observe maternal skin for adverse reactions. |
| Fertility Effects | No known effects on fertility in animal studies. Human data lacking. |